BLX 0279
Alternative Names: BLX-0279Latest Information Update: 18 Jan 2024
Price :
$50 *
At a glance
- Originator Biolexis Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action HDAC6 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease
Most Recent Events
- 18 Jan 2024 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Biolexis Therapeutics pipeline, January 2024)
- 18 Jan 2024 Preclinical trials in Huntington's disease in USA (unspecified route) (Biolexis Therapeutics pipeline, January 2024)
- 20 Sep 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) (Biolexis Therapeutics pipeline, January 2024)